Literatur
- 1
Abraldes J G. et al .
Hemodynamic response to pharmacological treatment of portal hypertension and
long-term prognosis of cirrhosis.
Hepatology.
2003;
37
902-908
- 2
Bosch J, Garcia-Pagán J C.
Prevention of variceal rebleeding.
Lancet.
2003;
361
952-954
- 3
Bureau C. et al .
„A la carte” treatment of portal hypertension: adapting medical therapy to hemodynamic
response for the prevention of bleeding.
Hepatology.
2002;
36
1361-1366
- 4
Lebrec D. et al .
Propranolol - a medical treatment for portal hypertension.
Lancet.
1980;
2 (8187)
180-182
- 5
Rasaratnam B. et al .
The effect of selective intestinal decontamination on the hyperdynamic circulatory
state in cirrhosis.
Ann Intern Med.
2003;
139
186-193
- 6
Schepke M. et al .
Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in
patients with cirrhosis and portal hypertension.
Gastroenterology.
2001;
121
389-395
- 7
Schepke M. et al .
Ligation versus propranolol for the primary prophylaxis of variceal bleeding
in cirrhosis.
Hepatology.
2004;
40
65-72
- 8
Shah V. et al .
Nitric oxide in gastrointestinal health and disease.
Gastroenterology.
2004;
126
903-913
- 9
Soares-Weiser K. et al .
Antibiotic prophylaxis of bacterial infections in cirrhotic inpatients: a meta-analysis
of randomized controlled trials.
Scand J Gastroenterol.
2003;
38
193-200
1 Dieses Manuskript wurde teilweise als Syllabusbeitrag für den Intensivkurs Klinische
Hepatologie in Offenbach, Juni 2004, verwandt.
Prof. Dr. Tilman Sauerbruch
Medizinische Klinik und Poliklinik I, Universitätsklinikum
Sigmund-Freud-Straße 25
53105 Bonn
Telefon: 0228/2875255
Fax: 0228/2874322
eMail: sauerbruch@uni-bonn.de
